Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesNeurosense Therapeutics Ltd

Neurosense Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.83 USD 0.05 ( 2.81%)
Last update at 2026-11-12T15:33:00Z
VOLUME
1026
Market Cap
19.66M

Momentum Score

…

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.82
Low
1.83
High
52 Week Price Range
0.40
Low
2.33
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures for Neurosense Therapeutics Ltd (NASDAQ: NRSN) indicate it is a small, R&D-focused company developing therapies for neurological conditions. Long-term growth drivers may include clinical progress, regulatory approvals and strategic partnerships that could support commercialization, and investors may find exposure to unmet central nervous system indications attractive if programs advance.
Key investment risks include early-stage development and financing risk — clinical trial failure, regulatory setbacks, competitive pressures and potential dilution — and investors should monitor the company’s cash runway and trial milestones.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.78
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.08
ROE
-602.40%
Net Debt
-2.54M
ROCE
4788.69%
Diluted EPS TTM
-0.78

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -12.34M -4.04M -2.83M -1.22M
Net income -11.20M -2.50M -2.83M -1.23M
Selling general administrative 7.14M 2.50M 0.39M 0.34M
Reconciled depreciation 0.09M 0.00M 0.00M 0.00M
Ebit -13.55M -5.59M -2.89M -1.24M
Ebitda -13.38M -8.28M -2.82M -1.25M
Depreciation and amortization 0.17M -2.70M 0.06M -0.02M
Operating income -13.55M -5.59M -2.89M -1.24M
Other operating expenses 13.55M 5.59M 2.89M 1.24M
Interest expense 0.01M 1.15M 0.00M 0.01M
Interest income 0.09M - 0.06M 0.02M
Net interest income 0.07M -1.15M 0.06M 0.01M
Income tax expense -1.14M -1.55M 0.00M 0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 13.55M 5.59M 2.89M 1.24M
Total other income expense net 1.21M 1.55M 0.06M 0.01M
Net income from continuing ops -12.34M -4.04M -2.83M -1.22M
Net income applicable to common shares - -4.04M -2.83M -1.22M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 3.18M 7.71M 11.43M 0.78M 0.95M
Other current assets 0.07M 3.84M 0.35M 0.04M -
Total liab 5.05M 2.09M 2.42M 0.12M 0.04M
Total stockholder equity -1.87M 5.62M 9.01M 0.66M 0.92M
Other current liab 1.93M 1.16M 0.56M 0.07M 0.01M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -32.07M -20.79M -8.45M -4.41M -1.58M
Other liab - - 1.83M - -
Other assets - - - 0.04M 0.04M
Cash 2.68M 3.54M 11.06M 0.70M 0.90M
Total current liabilities 3.46M 1.73M 0.60M 0.12M 0.04M
Net debt -2.54M -3.33M -11.06M -0.70M -0.90M
Short term debt 0.07M 0.06M - - -
Short long term debt total 0.14M 0.21M - - -
Other stockholder equity - 26.41M 17.45M 5.06M 2.50M
Property plant equipment - - 0.02M 0.01M 0.01M
Total current assets 2.92M 7.38M 11.41M 0.73M 0.91M
Net tangible assets - - 9.01M 0.66M 0.92M
Short term investments 0.00M 3.55M - - -
Net receivables 0.17M 0.13M 0.18M 0.03M 0.02M
Inventory - -3.68M -0.18M - -
Accounts payable 1.46M 0.50M 0.04M 0.06M 0.02M
Accumulated other comprehensive income 30.19M - - - -
Non currrent assets other 0.02M 0.02M - 0.04M 0.04M
Non current assets total 0.26M 0.33M 0.02M 0.05M 0.04M
Capital lease obligations 0.14M 0.21M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -3.54M -0.02M -0.01M -0.03M
Change to liabilities - -0.02M 0.03M 0.02M
Total cashflows from investing activities - -0.02M -0.01M -0.03M
Net borrowings - - - -0.00M
Total cash from financing activities 3.69M 11.90M 0.51M 1.42M
Change to operating activities - 0.49M 0.05M 0.01M
Net income -12.34M -4.04M -2.83M -1.22M
Change in cash -7.52M 10.36M -0.20M 0.81M
Begin period cash flow 11.06M 0.70M 0.90M 0.09M
End period cash flow 3.54M 11.06M 0.70M 0.90M
Total cash from operating activities -7.59M -1.54M -0.69M -0.58M
Issuance of capital stock 0.00M 9.86M 0.51M 1.42M
Depreciation 0.09M 0.00M 0.00M 0.00M
Other cashflows from investing activities - - - -0.02M
Change to account receivables - -0.20M -0.01M -0.00M
Other cashflows from financing activities 3.77M 2.04M -0.01M -0.03M
Change to netincome - 2.23M 2.06M 0.61M
Capital expenditures 0.07M 0.02M 0.01M 0.01M
Change in working capital 0.75M 0.27M 0.07M 0.03M
Stock based compensation 5.11M 4.16M 2.06M 0.61M
Other non cash items -1.19M 0.79M - -
Free cash flow -7.66M -1.56M -0.70M -0.59M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NRSN
Neurosense Therapeutics Ltd		 0.05
2.81%		 1.83 - - - 4.15 -2.01
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Neurosense Therapeutics Ltd

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Building B, Herzliya, Israel, 4672562

972 9 799 6183

https://www.neurosense-tx.com

18

Name Title Year Born
Mr. Alon Ben-Noon Co-Founder, CEO & Director 1979
Mr. Or Eisenberg Chief Financial Officer 1981
Ms. Hagit Binder VP of Operations 1978
Ms. Yael Barak Head of QA & Compliance 1970
Ms. Nedira Salzman-Frenkel Global Head of Bus. Devel. 1988
Dr. Shiran Zimri Ph.D. Head of Scientific Program 1985
Dr. Ferenc Tracik M.D. Chief Medical Officer 1965
Ms. Diana Shtossel Head of Regulatory Affairs 1979
Dr. Niva Russek-Blum Ph.D. Global Head of Discovery & IP Generator 1975
Dr. Sharon Cohen Vered Ph.D. Global Head of CMC 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…